OPEN ACCESS Freely available online

Medical & Surgical Urology

ISSN: 2168-9857

Commentary

Chimeric Antigen Receptor T Cells: Creating New Edges in Bladder Cancer Immunotherapy

Grzegorz Pranav*

Department of Surgical Urology, Wroclaw Medical University, Wrocław, Poland

DESCRIPTION

Bladder cancer remains a significant health challenge globally, with over 500,000 new cases diagnosed annually. It is often diagnosed at an advanced stage and despite recent advancements in treatment, the prognosis for patients with metastatic or inoperable bladder cancer remains poor. Traditional treatments such as surgery, chemotherapy and radiation therapy offer limited success, particularly in the face of tumour recurrence and resistance to treatment. In response to this challenge, researchers are analyze innovative immunotherapies like Chimeric Antigen Receptor T (CAR-T) cell therapy, which has shown promising results in treating other cancers like leukaemia and lymphoma. Although CAR-T therapy has not yet been widely implemented for bladder cancer, its potential to revolutionize bladder cancer treatment is gaining attention.

Understanding CAR-T cell therapy

CAR-T cell therapy is an immunotherapeutic approach that involves modifying a patient's T cells to better recognize and attack cancer cells. In CAR-T therapy, T cells are extracted from the patient's blood, genetically engineered in a laboratory to express a synthetic receptor that targets specific proteins on cancer cells and then reinfused into the patient's body.

These engineered T cells, equipped with Chimeric Antigen Receptors (CARs), can specifically bind to cancer cell antigens that would otherwise be ignored by the immune system. This approach has led to remarkable outcomes in hematologic cancers, such as Acute Lymphoblastic Leukaemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL), where CAR-T therapy has significantly improved survival rates.

Challenges in applying CAR-T to bladder cancer

Bladder cancer, particularly urothelial carcinoma, presents several unique challenges for CAR-T cell therapy. While hematologic cancers often express unique, easily targetable surface markers like CD19, solid tumors like bladder cancer are more complex. Bladder cancer cells often exhibit heterogeneous antigen expression, meaning that not all cancer cells within a tumour will express the same surface markers. This heterogeneity can complicate the effectiveness of CAR-T therapy, as some cancer cells might escape detection.

Additionally, the Tumour Micro-Environment (TME) of bladder cancer can be particularly hostile to CAR-T cells. The TME often contains immune-suppressive factors such as regulatory T cells, myeloid-derived suppressor cells and immune checkpoint molecules (like PD-L1) that dampen the immune response. This creates an environment where the CAR-T cells may be less effective or become exhausted before they can eliminate the tumour completely.

Recent developments in CAR-T for bladder cancer

Despite these challenges, recent studies and clinical trials are exploring innovative ways to overcome them. Researchers are focusing on identifying and targeting specific antigens expressed on bladder cancer cells. One promising target is the Epithelial Cell Adhesion Molecule (EpCAM), which is often overexpressed in bladder cancer. Another potential target is HER2, a receptor found in various cancers, including bladder cancer that can be targeted with CAR-T cells.

Studies have also looked at modifying the CAR-T cell design to enhance their ability to overcome the challenging TME. For example, strategies such as combining CAR-T cells with checkpoint inhibitors like anti PD-1 or anti CTLA-4 antibodies have been tested to counteract immune suppression in the tumour microenvironment. Additionally, combining CAR-T therapy with chemotherapy or radiation may enhance its effectiveness by reducing the immunosuppressive TME, making the tumour more vulnerable to CAR-T attack.

A notable example of this approach is the ongoing clinical trials investigating CAR-T therapies targeting Disialoganglioside (GD2), a GD2 expressed in some bladder cancers, in combination with immune checkpoint blockade. Early phase

Correspondence to: Grzegorz Pranav, Department of Surgical Urology, Wroclaw Medical University, Wrocław, Poland, E-mail: Grpranav@jhu.edu.pl

Received: 19-Nov-2024, Manuscript No. MSU-24-35911; **Editor assigned:** 21-Nov-2024, PreQC No. MSU-24-35911 (PQ); **Reviewed:** 06-Dec-2024, QC No: MSU-24-35911; **Revised:** 13-Dec-2024, Manuscript No: MSU-24-35911 (R); **Published:** 20-Dec-2024, DOI: 10.35248/2168-9857.24.13.373

Citation: Pranav G (2024). Chimeric Antigen Receptor T Cells: Creating New Edges in Bladder Cancer Immunotherapy. Med Surg Urol.13: 373.

trials have shown that this combination therapy could improve the durability of responses in bladder cancer patients who have not responded to conventional therapies.

Future prospects

While CAR-T cell therapy for bladder cancer is still in its early stages, the research to optimize its application shows promise. If these challenges can be overcome through better antigen identification, engineering more effective CAR-T cells and improving the tumour microenvironment CAR-T therapy could become a game-changer for patients with advanced or metastatic bladder cancer.

CAR-T cell therapy, particularly when combined with other treatments like immune checkpoint inhibitors or chemotherapy, has the potential to drastically improve the survival and quality of life for patients with bladder cancer. Ongoing trials and studies are expected to clarify on the effectiveness of these strategies and help establish the role of CAR-T therapy in bladder cancer treatment.

The role of AI and ml in prostate cancer diagnosis

Prostate cancer diagnosis traditionally relies on methods such as Digital Rectal Examination (DRE), Prostate Specific Antigen (PSA) testing, and biopsy. However, these techniques have limitations. PSA levels can be elevated due to Benign Prostatic Hyperplasia (BPH) or prostatitis, leading to false positives, while biopsies can miss aggressive cancers, particularly in cases where the tumour is located in hard to reach areas. These limitations underscore the need for more precise diagnostic tools, which is where AI and ML technologies come into play.

ML, a subset of AI, is capable of analyzing vast datasets and recognizing patterns in medical images, genomic data, and clinical histories. By learning from large amounts of data, ML algorithms can identify subtle patterns that may be undetectable by human experts. In prostate cancer, AI and ML are used to analyses imaging data from multipara metric Magnetic Resonance Imaging (mpMRI), digital pathology slides, and even genetic information.

AI in imaging: Enhancing prostate cancer detection

One of the most prominent applications of AI in prostate cancer diagnosis is in the analysis of imaging data. MpMRI is widely used in prostate cancer diagnosis to assess the prostate's anatomical features and detect suspicious lesions. AI-based tools have shown great promise in improving the interpretation of mpMRI scans, enhancing the ability to detect clinically significant prostate cancer.

AI algorithms can be trained on large datasets of annotated MRI images, allowing them to learn how to distinguish between benign and malignant tissues with high accuracy. These systems can automatically segment the prostate and identify regions of interest, reducing the time and effort required for radiologists to interpret images. AI tools have also demonstrated the ability to predict tumour aggressiveness by analyzing the texture and other characteristics of the lesions. The use of AI in mpMRI analysis has been shown to reduce the inter reader variability seen among radiologists, leading to more consistent diagnoses.

ML in pathology: Revolutionizing histopathology

Another area where AI and ML are making a significant impact is in the field of pathology. Prostate cancer diagnosis often involves histopathological examination of biopsy samples, where pathologists assess the tissue for signs of malignancy, grade the tumour and determine its stage. AI and ML have been introduced to assist pathologists in this process.

Integrating genomics and clinical data with AI

AI and ML also hold promise in the integration of genomics and clinical data to improve the precision of prostate cancer diagnosis. The genetic makeup of a prostate tumour can offer valuable insights into its behavior and potential response to treatment. Machine learning algorithms can analyse genomic data from sequencing platforms to identify mutations and gene expression patterns associated with prostate cancer progression and treatment resistance.

In addition to genomic data, AI systems can integrate clinical data such as PSA levels, age, family history and comorbidities to develop more personalized diagnostic models. By analyzing these diverse datasets, AI can help identify patients who are at high risk for aggressive disease and those who may benefit from earlier interventions.

Benefits and challenges of ai in prostate cancer diagnosis

The use of AI and ML in prostate cancer diagnosis offers several advantages. First and foremost, it enhances the accuracy and precision of diagnoses, reducing the likelihood of false positives and false negatives. This leads to earlier detection of clinically significant cancers and helps avoid unnecessary biopsies or treatments for indolent cancers.

CONCLUSION

AI and ML have the potential to transform prostate cancer diagnosis, making it more accurate, timely and personalized. With advancements in imaging, pathology and genomics, AI is poised to enhance early detection and improve treatment outcomes, ultimately leading to better quality of life for patients. As technology continues to evolve, these innovations will likely play an increasingly central role in prostate cancer care.